These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26039601)

  • 1. Vasopressin antagonists.
    Berl T
    N Engl J Med; 2015 Jun; 372(23):2207-16. PubMed ID: 26039601
    [No Abstract]   [Full Text] [Related]  

  • 2. Vasopressin Antagonists.
    Vandergheynst F; Gankam Kengne F; Decaux G
    N Engl J Med; 2015 Sep; 373(10):980-1. PubMed ID: 26332562
    [No Abstract]   [Full Text] [Related]  

  • 3. Vasopressin Antagonists.
    Berl T
    N Engl J Med; 2015 Sep; 373(10):981. PubMed ID: 26332561
    [No Abstract]   [Full Text] [Related]  

  • 4. Vasopressin receptor antagonists: Characteristics and clinical role.
    Rondon-Berrios H; Berl T
    Best Pract Res Clin Endocrinol Metab; 2016 Mar; 30(2):289-303. PubMed ID: 27156765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressin receptor antagonists in patients with chronic heart failure.
    De Vecchis R; Cantatrione C; Mazzei D
    Herz; 2017 Aug; 42(5):492-497. PubMed ID: 27628642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction: Vasopressin therapy.
    Whellan DJ
    Heart Fail Rev; 2009 Jun; 14(2):57-8. PubMed ID: 18989773
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of hyponatremia: the role of lixivaptan.
    Liamis G; Filippatos TD; Elisaf MS
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):431-41. PubMed ID: 24766294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of tolvaptan in patients with hyponatremia due to heart failure: initial experience.
    Rodríguez-de Muñoz YM; Sánchez-Lázaro IJ; Almenar-Bonet L; Martínez-Dolz L; Rodríguez-Serrano M; Salvador-Sanz A
    Rev Esp Cardiol (Engl Ed); 2013 Apr; 66(4):319-21. PubMed ID: 24775629
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
    J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tolvaptan in patients hospitalized for heart failure with refractory hyponatremia. Clinical experience in daily practice.
    Salterain-Gonzalez N; Esteban-Fernández A; García-López M; Lavilla-Royo FJ; Gavira-Gómez JJ
    Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):503-4. PubMed ID: 24776057
    [No Abstract]   [Full Text] [Related]  

  • 11. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
    Lin TE; Adams KF; Patterson JH
    Heart Fail Clin; 2014 Oct; 10(4):607-20. PubMed ID: 25217436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyponatremia now--a goldmine or a dead end?
    Gross P
    Adv Clin Exp Med; 2012; 21(5):559-61. PubMed ID: 23356191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyponatremia in heart failure: concluding remarks.
    Chatterjee K
    Heart Fail Rev; 2009 Jun; 14(2):87-8. PubMed ID: 18758942
    [No Abstract]   [Full Text] [Related]  

  • 14. Vasopressin-receptor antagonists.
    Hoorn EJ; Zietse R
    Future Cardiol; 2010 Jul; 6(4):523-34. PubMed ID: 20608824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The pathway of vasopressin as a pharmacological target in nephrology: a narrative review].
    Recupero M; Fulignati P; Naticchia A; D'Alonzo S; D'Ascenzo F; Costanzi S
    G Ital Nefrol; 2018 Dec; 35(6):. PubMed ID: 30550035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of vasopressin receptor antagonists in hyponatremia.
    Khanna A; Menon MC
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A snake toxin as a theranostic agent for the type 2 vasopressin receptor.
    Droctové L; Lancien M; Tran VL; Susset M; Jego B; Theodoro F; Kessler P; Mourier G; Robin P; Diarra SS; Palea S; Flahault A; Chorfa A; Corbani M; Llorens-Cortes C; Mouillac B; Mendre C; Pruvost A; Servent D; Truillet C; Gilles N
    Theranostics; 2020; 10(25):11580-11594. PubMed ID: 33052234
    [No Abstract]   [Full Text] [Related]  

  • 18. A history of diabetes insipidus: paving the road to internal water balance.
    Eknoyan G
    Am J Kidney Dis; 2010 Dec; 56(6):1175-83. PubMed ID: 20888099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin-receptor antagonist therapy in patients with hyponatraemia.
    Vachharajani T; Vachharajani V
    Br J Hosp Med (Lond); 2007 Jul; 68(7):367-72. PubMed ID: 17663307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New horizons in the pharmacologic approach to hyponatremia: the V2 receptor antagonists.
    Palmer BF
    J Hosp Med; 2010; 5 Suppl 3():S27-32. PubMed ID: 21157907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.